Deferoxamine promotes angiogenesis via the activation of vascular endothelial cell function

Atherosclerosis

Volumn 215, Issue 2, 2011, Pages 339-347

  Ikeda, Yasumasa ^a   Tajima, Soichiro ^a   Yoshida, Sumiko ^a   Yamano, Noriko ^a   Kihira, Yoshitaka ^a   Ishizawa, Keisuke ^a   Aihara, Ken Ichi ^a   Tomita, Shuhei ^a   Tsuchiya, Koichiro ^a   Tamaki, Toshiaki ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Angiogenesis; Endothelial cells; Endothelial nitric oxide synthesis (eNOS); Iron chelator

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; DEFEROXAMINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BLOOD FLOW; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME PHOSPHORYLATION; HEMATOPOIESIS; HUMAN; HUMAN CELL; IN VIVO CULTURE; LIMB ISCHEMIA; MUSCLE ISCHEMIA; OXIDATIVE STRESS; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; DEFEROXAMINE; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HINDLIMB; HUMANS; IRON CHELATING AGENTS; ISCHEMIA; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 79953031023     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.01.009     Document Type: Article

References (30)

1. Cianciulli P., Sorrentino F., Maffei L., Amadori S. Continuous low-dose subcutaneous desferrioxamine (DFO) to prevent allergic manifestations in patients with iron overload. Ann Hematol 1996, 73:279-281.
2. Andrews N.C. Disorders of iron metabolism. N Engl J Med 1999, 341:1986-1995.
3. Galaris D., Skiada V., Barbouti A. Redox signaling and cancer: the role of " labile" iron. Cancer Lett 2008, 266:21-29.
4. Beerepoot L.V., Shima D.T., Kuroki M., Yeo K.T., Voest E.E. Up-regulation of vascular endothelial growth factor production by iron chelators. Cancer Res 1996, 56:3747-3751.
5. Linden T., Katschinski D.M., Eckhardt K., Scheid A., Pagel H., Wenger R.H. The antimycotic ciclopirox olamine induces HIF-1alpha stability, VEGF expression, and angiogenesis. FASEB J 2003, 17:761-763.
6. Ishizaka N, Saito K., Mitani H., et al. Iron overload augments angiotensin II-induced cardiac fibrosis and promotes neointima formation. Circulation 2002, 106:1840-1846.
7. Lee T.S., Shiao M.S., Pan C.C., Chau L.Y. Iron-deficient diet reduces atherosclerotic lesions in apoE-deficient mice. Circulation 1999, 99:1222-1229.
8. Ramakrishna G., Rooke T.W., Cooper L.T. Iron and peripheral arterial disease: revisiting the iron hypothesis in a different light. Vasc Med 2003, 8:203-210.
9. Menke A., Fernandez-Real J.M., Muntner P., Guallar E. The association of biomarkers of iron status with peripheral arterial disease in US adults. BMC Cardiovasc Disord 2009, 9:34.
10. Kocher A.A., Schuster M.D., Szabolcs M.J., et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001, 7:430-436.
11. Shiojima I, Sato K., Izumiya Y., et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 2005, 115:2108-2118.
12. Murohara T., Asahara T., Silver M., et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 1998, 101:2567-2578.
13. Chekanov V.S., Zargarian M., Baibekov I., et al. Deferoxamine-fibrin accelerates angiogenesis in a rabbit model of peripheral ischemia. Vasc Med 2003, 8:157-162.
14. Chekanov V.S., Nikolaychik V., Maternowski M.A., et al. Deferoxamine enhances neovascularization and recovery of ischemic skeletal muscle in an experimental sheep model. Ann Thorac Surg 2003, 75:184-189.
15. Ikeda Y., Ohashi K., Shibata R., et al. Cyclooxygenase-2 induction by adiponectin is regulated by a sphingosine kinase-1 dependent mechanism in cardiac myocytes. FEBS Lett 2008, 582:1147-1150.
16. Ikeda Y., Aihara K., Akaike M., et al. Androgen receptor counteracts doxorubicin-induced cardiotoxicity in male mice. Mol Endocrinol 2010, 24:1338-1348.
17. Tajima S., Tsuchiya K., Horinouchi Y., et al. Effect of angiotensin II on iron-transporting protein expression and subsequent intracellular labile iron concentration in human glomerular endothelial cells. Hypertens Res 2010, 33:713-721.
18. Ikeda Y., Aihara K., Sato T., et al. Androgen receptor gene knockout male mice exhibit impaired cardiac growth and exacerbation of angiotensin II-induced cardiac fibrosis. J Biol Chem 2005, 280:29661-29666.
19. Dimmeler S., Fleming I., Fisslthaler B., Hermann C., Busse R., Zeiher A.M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999, 399:601-605.
20. Fulton D., Gratton J.P., McCabe T.J., et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999, 399:597-601.
21. Galasso G., Schiekofer S., Sato K., et al. Impaired angiogenesis in glutathione peroxidase-1-deficient mice is associated with endothelial progenitor cell dysfunction. Circ Res 2006, 98:254-261.
22. Dai S., He Y., Zhang H., et al. Endothelial-specific expression of mitochondrial thioredoxin promotes ischemia-mediated arteriogenesis and angiogenesis. Arterioscler Thromb Vasc Biol 2009, 29:495-502.
23. Asikainen T.M., Ahmad A., Schneider B.K., et al. Stimulation of HIF-1alpha, HIF-2alpha, and VEGF by prolyl 4-hydroxylase inhibition in human lung endothelial and epithelial cells. Free Radic Biol Med 2005, 38:1002-1013.
24. Tanji K, Imaizumi T., Matsumiya T., et al. Desferrioxamine, an iron chelator, upregulates cyclooxygenase-2 expression and prostaglandin production in a human macrophage cell line. Biochim Biophys Acta 2001, 1530:227-235.
25. Woo K.J., Lee T.J., Park J.W., Kwon T.K. Desferrioxamine, an iron chelator, enhances HIF-1alpha accumulation via cyclooxygenase-2 signaling pathway. Biochem Biophys Res Commun 2006, 343:8-14.
26. Jones M.K, Wang H., Peskar B.M., et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999, 5:1418-1423.
27. Dongiovanni P., Valenti L., Ludovica Fracanzani A., Gatti S., Cairo G., Fargion S. Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. Am J Pathol 2008, 172:738-747.
28. Alvarez-Tejado M., Naranjo-Suarez S., Jimenez C., Carrera A.C., Landazuri M.O., del Peso L. Hypoxia induces the activation of the phosphatidylinositol 3-kinase/Akt cell survival pathway in PC12 cells: protective role in apoptosis. J Biol Chem 2001, 276:22368-22374.
29. Philipp S., Cui L., Ludolph B., et al. Desferoxamine and ethyl-3, 4-dihydroxybenzoate protect myocardium by activating NOS and generating mitochondrial ROS. Am J Physiol Heart Circ Physiol 2006, 290:H450-457.
30. Ishizaka N., Saito K., Mori I., Matsuzaki G., Ohno M., Nagai R. Iron chelation suppresses ferritin upregulation and attenuates vascular dysfunction in the aorta of angiotensin II-infused rats. Arterioscler Thromb Vasc Biol 2005, 25:2282-2288.